"We no longer need to endure the ravages of ageing"

Ageing is a natural part and the "last mile" of a human development programme, and Gero pioneered ways to understand, measure, and, ultimately, control its progression. Gero, a longevity biotech physics-enabled biotechnology company from Singapore is creating therapeutics against chronic diseases with a mission to slow down human ageing itself.

Gero's machine-learning platform possesses the unique capability to identify potential therapeutic targets for fibrotic diseases by analysing extensive human-based datasets. These discoveries could potentially reshape the landscape of anti-ageing research. In January 2023, the American pharmaceutical giant entered the longevity field by collaborating with Gero. Maxim Kholin, Founder of Gero, takes us through the exciting science of antiageing/longevity and why it is no longer confined to the realm of science fiction. Edited excerpts:

What technologies is Gero using to solve ageing?

To my knowledge, we are the only company that is using physics to model biology this way. For example, consider how we approach this. People can predict the trajectory of planetary movement, much like how we analyse vast medical datasets, such as electronic medical records. We discern patterns in the data, akin to predicting future states using equations of motion, and anticipate how a patient's condition may change after therapy, similar to how Gmail suggests sentence completions as you type. Our internal projects are focused on addressing the challenge of ageing, including partial rejuvenation and halting the ageing process. Furthermore, we're actively seeking new rounds of investment to advance anti-ageing therapies and undertake additional projects related to age-related diseases.